"Building a deep tech company or building anything, pretty much, like being a founder in anything, it's like planning a bank robbery. It's like putting together a crew where, you know, you need a driver, you need someone to pick locks, you need someone to not sell, and you need someone who has the intellectual capacity to come up with a plan."
In this episode of The Biotech Startups Podcast, Sergey Jakimov, Managing Partner at LongeVC, shares his journey from uncertain graduate student in Budapest to serial deep tech founder. He discusses launching his first startup at age 22 in the conservative oil and gas industry with zero experience, pioneering drug-eluting coatings for orthopedic implants, and building Lungesys—a clinical data platform that revolutionized trial patient recruitment and helped establish the world's largest biobank.
Sergey challenges the "dropout culture" narrative while defending both formal education and learning by doing. He reveals why the least specialized person often makes the best founder and shares surprising truths about big pharma, including that only 14% of first-in-class cancer drugs are developed internally.
🧬 The Biotech Startups Podcast is powered by Excedr—helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science.
As a
TBSP listener, you can get exclusive perks through Excedr’s partner network—special savings, promotions, and more. Explore these offers today:
https://www.excedr.com/partners.
Episode Description:
"Building a deep tech company or building anything, pretty much, like being a founder in anything, it's like planning a bank robbery. It's like putting together a crew where, you know, you need a driver, you need someone to pick locks, you need someone to not sell, and you need someone who has the intellectual capacity to come up with a plan."
In this episode of The Biotech Startups Podcast, Sergey Jakimov, Managing Partner at LongeVC, shares his journey from uncertain graduate student in Budapest to serial deep tech founder. He discusses launching his first startup at age 22 in the conservative oil and gas industry with zero experience, pioneering drug-eluting coatings for orthopedic implants, and building Lungesys—a clinical data platform that revolutionized trial patient recruitment and helped establish the world's largest biobank.
Sergey challenges the "dropout culture" narrative while defending both formal education and learning by doing. He reveals why the least specialized person often makes the best founder and shares surprising truths about big pharma, including that only 14% of first-in-class cancer drugs are developed internally.
Key topics covered:
- The "Bank Heist Model" of Team Building: Why founders should assemble specialists rather than be experts in everything
- Three Startup Journey: From CFD engineering to medical devices to clinical data platforms
- Education vs. Experience Debate: Defending formal education while emphasizing learning by doing
- Clinical Trial Innovation: Streamlining patient recruitment and building the world's largest biobank
- Big Pharma Reality Check: Debunking misconceptions about how the pharmaceutical industry operates
If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening.
Subscribe to the Podcast:
Find our guest, Sergey Jakimov, at these links:
Find our host, Jon Chee, at these links:
Learn more about Excedr:
Intro & Outro Songs Created by OkKyojin, Owned by Excedr:
Resources & Articles:
Companies, Universities, & People mentioned:
Timestamps:
00:00 Intro
01:52 Student Life in Budapest
03:03 The "What's Next?" Uncertainty
08:39 First Company: CFD Modeling and Oil & Gas at 22
12:54 Second Company: Medical Devices and Drug-Eluting Coatings
17:07 The Bank Heist Model of Assembling Teams
20:25 The Value of Education vs. Dropout Culture
25:46 Hard Skills and Breaking Paradigms
28:41 Teaching IP and Venture Capital
29:52 Third Company: Clinical Data and Lungesys
38:10 Selling to Big Pharma
41:14 Outro